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Summary.-Sera from 16 of 20 patients with AML at some stage of the disease
inhibited the in vitro PHA transformation of normal lymphocytes assessed by
measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera
were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3
times greater than the concentration which allowed maximum discrimination
between NHS and leukaemia sera.
PHA transformation of washed lymphocytes obtained from AML patients before
treatment and when receiving induction or consolidation (cytoreductive) chemo-
therapy was reduced only when cultures contained a high proportion of primitive
cells. Even in primitive cell contaminated cultures significant responses to PHA
could be measured if conditions were modified to prevent increasing acidity.
Reports of reduced in vitro immunological reactions in pretreatment and poor
prognosis patients may therefore be due to the presence ofprimitive cells in culture,
and in treated patients to the failure of chemotherapy to reduce the circulating
primitive cell count. Serum inhibitory factors may have a significant immuno-
suppressive effect in vivo, but the accurate assessment of the role of immune mechan-
isms in AML should attempt the measurement of specific immunity.
THE importance ofa failure of immune
mechanisms in the aetiology of human
leukaemia is unknown and will depend
primarily upon the identification of anti-
gens specific for human leukaemia (Harris,
1973). Autologous acute leukaemia blast
cells have been shown to stimulate the
in vitro transformation of remission
lymphocytes (Viza et al., 1969; Fridman
and Kourilsky, 1969) probably because
they possessed " new " antigens. There-
fore the study of lymphocyte dependent
immune reactions in acute leukaemia is
justified.
The in vitro lymphocyte response
to phytohaemagglutinin (PHA), regarded
as a test of " T " cell mediated immunity
(Doenhoff et al., 1971), is superficially
easy to measure and accordingly has
been wi(lely applied in leukaemia as in
many other disorders. Previous studies
have indicated that lymphocytes of
patients with acute lymphoblastic leuk-
aemia (ALL) before treatment (Astaldi
et al., 1966), when receiving intensive
treatment (Bardare et al., 1969) and in
remission (Jones et al., 1971) have normal
PHA responses. In contrast, in patients
with acute myeloid leukaemia (AML)
before treatment, Hersh et al. (1971)
found that a low PHA response which
did not become normal after intensive
chemotnerapy was associated with a
failure to achieve remission, whereas
patients with normal pre- and post-
treatment responses achieved remission.
These results, together with the results
of other in vivo and in vitro tests of
lymphocyte reactivity, suggested that
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competence (luring treatment had a poor
prognosis. However, the in vitro PHA
test is open to considerable technical
variation- the dose of PHA used must be
carefully determined from normal lympho-
cyte dose-response curves (Fitzgerald,
1971) and in some studies, as indicated
by Jones et al. (1971), excessive quantities
of PHA may have been used. Other
studies have failed to (listinguish between
an intrinsic defect in lymphocyte function
an(d the inhibitory effects noted by
Freeman et al. (1973) of autologous AML
serum included in the culture medium.
We have extended our earlier studies
of the effect of serum from patients with
AML on the lymphocyte response to
PHA, and have compared with the normal
the PHA responses of patients before
treatment and when receiving intensive
chemotherapy. The effect on the PHA
response of large numbers of leukaemic
blastoid cells in untreated AML is also
reported.
MATERIALS AND METHODS
1. Leukaeinia patients and treatment
A total of 20 patients with AMI, were
studied. Patients on induction chemothe-
rapy received cytosine arabinoside (2-0
mg/kg body weight) daily for 5 days by
intravenous injection and daunorubicin (1.5
mg/kg) intravenously on the first day only,
followed by 5 days without chemotherapy,
this period being prolonged if the bone
marrow showed marked hypoplasia. The
course was repeated until the patients were
in complete remission, wAhen one further
course was given. Patients in remission
received consolidation therapy with intra-
venous cyclophosphamide (200 mg/M2 wsNeekly
and oral thioguanine 2-5 mg/kg daily),
continuing for 6 weeks or until not more
than 3 months from the start of chemothe-
rapy. One patient received immunotherapy
weekly by subcutaneous injections of 108-109
irradiated, allogeneic blast cells (previously
stored at -1960C) into 3 limbs, BCG being
injected into the fourth limb.
In most cases ' pretreatment sample"
refers to blood specimens taken before any
treatment. Houwever, in a fe-w cases the
patients may have received blood trans-
fusion, antibiotics and, very rarely, drugs
such as prednisolone but not chemotherapy.
2. LyTmphocyte cultures
(a) Separation of lymphocytes.-Lympho-
cyte rich plasma was prepared from defi-
brinated blood by a modification of the
carbonyl iron method of Coulson and Chal-
mers (1967), in which plasmagel (Laboratoire
Roger Bellon) (3 ml/10 ml blood) was used
to sediment red blood cells. After counting
morphologically small lymphocytes, the cells
were sedimented by centrifugation (350 g,
10 min) and washed once with TC199 culture
medium (Welleome) to remove autologous
plasma. Sterile, disposable plastic bottles
(Sterilin) were used for lymphocyte pre-
paration.
(b) Culture conditions.-(i) Forthe estima-
tion of lymphocyte reactivity to PHA (Difco
PHA-P control 551099) the cell pellet was
resuspended in TC199 and normal human
serum (0.4 ml NHS/ml TC199) with 0 5-
0-7 x 106 lymphocytes in 1-4 ml of medium.
Suspensions were usually contaminated with
10-20 times this number of red blood cells
and a smaller number (< 105) of poly-
morphonuclear leucocytes. To 1-4 ml of cell
suspension in glass culture tubes (Pyrex
72 x 10 mm) was added 0-6 ml of TC199
medium, with or without a known amount
of PHA (usual final concentration in cul-
tures= 7-2 ,tg/ml).
(ii) For the estimation ofserum inhibitory
activity, washed cells obtained from a
healthy donor were suspended in TC199 so
that 1 ml aliquots contained 0-3-0-5 x 106
lymphocytes. One ml aliquots of cell sus-
pension were rapidly transferred to culture
tubes containing 0-4 ml of serum (leukaemic
or NHS, previously stored at -20°C and
thawed only once) and then 0-6 ml of TC199
medium with or without PHA (final con-
centration 7-2 ,tg and 21-6 ,ug/ml of culture)
was added. Final serum concentration in
all cultures was 20% and only serum from
ABO compatible donors w-as used; conse-
quently cultures always contained red blood
cells.
Culture tubes were sealed with Parafilm
(Gallenkamp) and after careful mixing were
incubated vertically at 37°C for 67-70
hours.
Preliminary experiments, in which lymph-
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wNith various concentrations of PHA for
various time intervals, indicated that with
this batch of PHA the time of maximum
DNA synthesis was between 48 and 72
hours after the start of cultures and with a
PHA concentration of 7-2 ,ug/ml.
3. Estimation of DNA synthesis
The method used was similar to that
described by Craig, Garrett and Jackson
(1969). Briefly, 041 ml of [1251] 5-iodo
2'deoxyuridine solution (0.021 mg/ml, 20
,uc/ml at Day 0) was added to each culture
tube and after mixing, cultures were incu-
bated for a further one hour at 37TC. Culture
tubes were then centrifuged (350 g, 10 min),
the supernatant discarded and the cells
washed once with 2 ml of Hank's balanced
salt solution (HBSS) and resedimented.
Cell pellets were stored at - 20°C until
required. After thawing, 1 ml of bovine
serum (4 mg/ml) was added, followed by
1-5 ml of cold 10% (wAr/v) trichloracetic acid
and the precipitate was dispersed and
sedimented (850 g, 10 miii). The sediment
Nwas washed once wsith 2 ml of cold 500
(wA/v) trichloracetic acid and resedimented.
y emission of the pellets was assayed with
a Wallac Autogamma Counter (GTL 300)
at a detection efficiency of 38%.
The optimum concentration of 5-iodo
2'deoxyuridine to be added to cultures was
determined in control experiments in which
concentrations below 1 05 x 10-4 mg/culture
were rate limiting, whilst at 2-1 x 10-4
mg/culture 5-iodo 2'deoxyuridine was in
excess without being inhibitory. The rate
of 1251 uptake measured after one hour in
these conditions continued for a further
2-3 h-ours.
of 10 x 106 per culture. Higher lympho-
cyte concentrations were inhibitory.
In the analyses log10 of PHA (7.2,ug/ml
culture) response was assumed to be normally
distributed.
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FIG. 1. MAean PHA dose-response curve for lympho-
cytes from 10 normal individuals (broken lines
indicate 2 S.D. limits for mean response at 7 - 2 and
14- 4 jig PHA/ ml culture).
4. Assessment of results
Measured count rates were corrected for
the decay in 1251 specific activity and for
detection efficiency. PHA response wias
defined as dpm per hour of incubation time
per 0 5 x 106 lymphocytes added to cultures
at zero time. Responses in cultures con-
taining less than 0 5 x 106 lymphocytes
were corrected using a calibration curve.
125I uptake was found to increase linearly
as the zero time lymphocyte concentration
increased from 0-2 to 0 5 x 106 per culture.
A maximum uptake was then attained
hich as constant up to concentrations
14
of autologous and allogeneic NHS were
obtained from 10 healthy individuals.
From these the lowest concentration
(approximately 7-2 ,ag/ml culture) which
gave the maximum PHA response was
determined. Sera under investigation for
inhibitory activity were tested with maxi-
mum sensitivity in cultures containing
7*2 ,ug/ml of PHA and with normal
lymphocytes showing dose responses simi-
lar to the mean.
The variation in response obtained
with 10 different allogeneic NHS was
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measured using lymphocytes from 1-3
healthy individuals. The response with
each allogeneic serum was expressed as
a percentage of the response of the cells
when cultured in autologous NHS. In
a total of 22 tests the mean response in
allogeneic NHS was 100% with a range
of values of 75-125%.
Sera from AML patients were tested
individually in batches of 8-12 with 2-3
allogeneic NHS controls. The responses
in the presence of leukaemia sera were
expressed as percentages of the mean
response with NHS, and are shown in
Table I.
Of 92 sera obtained from 20 patients
at various stages of treatment 36 (390o)
were found to be inhibitory (Table Ia).
Of 64 sera collected from 7 patients in
remission only 6 (10%), all from the
patient (AR) receiving immunotherapy,
were inhibitory. Table lb shows that
inhibitors were present in the serum of
42% of patients before treatment, and
80% of patients undergoing chemothe-
rapy but not in remission. In contrast,
TABLE I. Frequency of Occurrence in
AML of Sera which Inhibit the PHA
(7.2 1tg/ml culture) Response of Normal
Lymphocytes
la. Number of sera.
Inhibitory range Number
r of
Stage of disease - +* + +t patients
Pretreatment . 11 5 3 . 19
Acute phase and re-
lapse: 56 30 6 20
Remission 58 6 0 . 7
* Response 25-75% of NHS control.
t Response= 0-25% of NHS control.
I Includes patients on induction chemotherapy.
lb. Number of patients: Inhibition was said to be
present if it could be detected in one or more
serum specimen.
Inhibition
Stage of disease Absent
Pretreatment 11
Acute phase and re-
lapse . 4
Remission . . 6*
* On chemotherapy only.
t On immunotherapy.
t Present
8
Total
number
19
16 . 20
it 7
only one (AR) out of 6 patients in
haematological remission could be shown
to have inhibitors.
With the exception of AR, inhibitory
sera did not contain HL-A antibodies
detectable in a micro-lymphocytotoxic
test (Harris et al., 1970).
Studies of serial specimens of serum
from AR were carried out. A serum
obtained during the early stages of
induction chemotherapy inhibited the
PHA response of all the allogeneic normal
lymphocytes tested and also completely
depressed the response of autologous
lymphocytes which responded to PHA
when cultured with TC199 20% NHS
(Fig. 2). Initial results with this serum
indicate that on titration with sterile,
pooled AB serum 1600 of inhibitory
activity was lost at a 1: 1 dilution, 66%
at 1 :3, 840 atl :7and 950 atI :15.
Later serum specimens from AR obtained
during chemotherapy induced remission
showed no inhibitory activity. However,
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Fie. 2. Inhibitory effect of AML serum on PHA
response of autologous washed lymphocytes
measured by 125IUdR uptake. NHS = normal
human serum.
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when AR received immunotherapy with
allogeneic blast cells she developed anti-
bodies directed against HL-A 10, 12, 13
and W10 and her serum now showed a
much more restricted inhibitory pattern,
for example, it completely inhibited the
PHA (7.2 ,ug/ml culture) response of
allogeneic lymphocytes with the HL-A
phenotype 3, 12, Te58, but the response
of autologous lymphocytes and lympho-
cytes of a donor with HL-A phenotype 2,
9, LND were normal.
The effect of PHA concentration on
inhibition was investigated using 5 sera
which gave more than 800o inhibition
ofthe normal lymphocyte PHA (7.2 ,ug/ml
culture) response. The values for each
serum at 7.2 ,ug PHA/ml culture were
6 o, 200' 20, 30 and 15 o of the NHS
response, whilst at 21.6 lug PHA/ml
culture the values were respectively 106%,
1100/, 146%, 56% and 107% of the
NHS response at 7.2 lug PHA/ml culture.
In all cases the inhibitory effect of the
leukaemia sera was reduced or abolished
at the hiaher PHA concentration. Inhibi-
tion in sera from patient AR due to
HL-A antibodies was also abolished at
higher PHA concentrations (21.6 /,g/ml
culture).
Four leukaemia sera (not containing
detectable HL-A antibodies) which
strongly inhibited the PHA response
were also tested in the 2-way mixed
lymphocyte culture with a final concen-
tration in the culture medium of 2000.
The 125IUdR uptakes measured in a
3-hour incubation period after 6 days
culture were 30%0, 41%0 48% and 62%
of the uptakes with similar cultures
containing 20% NHS.
The PHA (7a2 pg/ml culture) reactivity of
washed lymiphocytes from AML patients
Before treatment most AML patients
had circulating blastoid or other primitive
cells and therefore lymphocyte cultures
of these patients were almost always
contaminated with primitive cells, making
comparison with normal lymphocyte cul-
tures difficult. However, the circulating
TABLE II. Log1o PHA (7.2 ag/ml cul-
ture) Response in NHS of Lympho-
cytes from AML Patients Receiving
Chemotherapy
No. of No. of
patients tests
Induction
chemotherapy
Normal
Log,0 PHA
response
(mean±2 SD)
18 . 44 . 4-5471±0*2624
10 . 19 . 4-4530±0 3501
blastoid cell population was substantially
reduced following the start of induction
chemotherapy. The PHA (7.2 ,ug/ml
culture) responses of washed lymphocytes
from these patients could then be com-
pared with the responses of normal
lymphocytes. Table II shows that there
were no significant differences between
the responses of normals and leukaemics.
The PHA (7.2 ,ug/ml culture) responses
of 3 patients, measured repeatedly during
induction and consolidation stages of
chemotherapy, showed a greater propor-
tion of high responses during the con-
solidation stage (Fig. 3). The differences
between the means of the log1o induction
responses (4.3677) and the log1o con-
solidation responses (4.8214) were signi-
ficant (P 0.05).
The effect of the presence of primitive cells
on the in vitro PHA (7.2 ag/ml culture)
response
With cultures oflymphocytes obtained
from AML patients before treatment
there was an inverse relationship between
the number of primitive cells (usually
myeloblasts) present and the PHA res-
ponse. When the circulating primitive
cell concentration was > 8000/mm3 (>ap-
proximately 5 x 106 primitive cells/0.5 x
106 lymphocytes/culture), the PHA res-
ponses were more than 2 standard devia-
tions below the normal mean value and
in many cases were not significantly
greater than values obtained in control
cultures without PHA. However, when
circulating primitive cell concentrations
were low (< 8000/mm3 and < approxi-
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FIG. 3.-PHA responses (measured by 125IUdR
uptake) of 3 AML patients during induction and
consolidation chemotherapy. + patient 1, 0
patient 2, * patient 3.
mately 5 x 106 primitive cells/0.5 x 106
lymphocytes/culture) PHA responses did
not usually differ significantly from normal
(Fig. 4).
In order to investigate the cause of
low responses in cultures containing large
numbers of primitive cells 3 types of
+ 2 SD
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MEAN
) - 2 SD
ER I OR 2
TREATMENT COURSES OF
INDUCTION
CHEMOTHERAPY
Fio. 4. Effect of induction chemotherapy on the
PHA response, measured by 125IUdR uptake, of
pretreatment AML patients. 0 patients with no
circulating primitive cells, O patients with less
than 8000/mm3 circulating primitive cells, 0
patients with more than 8000/mm3 circulating
primitive cells.
culture were set up: (1) in sealed tubes
(standard culture conditions); (2) in loose
capped tubes (cotton wool plug); (3) in
sealed tubes with a change of medium
after 24 and 48 hours of culture (Table
III).
TABLE III.-Effect ofExperimental Conditions on PHA (7.2 ,ug/ml Culture) response
in Cultures Containing a HighProportion ofprimitive Cells
Individual
AML patient No. 1
AML patient No. 2
Normal volunteer No. 1
Cell count/culture
Lymphocyte: 0 72x 106
Primitive cell: 13 4 x 106
Lymphocyte: 0- 71 x 106
Primitive cell: 5- 5x 106
Lymphocyte: 0*53x 106
c
Normal volunteer No. 2 Lymphocyte: 0 65x 106
* 1 ml of supernatant was removed and replaced by
PHA (7-2 ,tg/ml) or without PHA for control tubes.
Culture conditions
_- _- A
Sealed tube Loose capped
PHA medium tube
concn Sealed change at 24 cotton-wool
(yg/ml tube and 48 h* plug
ulture) (Ipm/0 5 x 106 lymphocytes/h
0
7-2
0
7 -2
0
7 -2
0
7 -2
4155
5583
1866
3246
530
21746
706
40938
7504
18711
12472
21973
532
26373
748
37108
15458
32569
7593
12115
731
10993
650
3543
1 ml of TC199 medium/20% serum containing
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In the loose capped and medium
change AML cultures the control res-
ponses (no PHA added) were greater
than those measured in sealed tubes.
The pH remained in the range 7-2-7-4
in loose capped cultures and was restored
to this pH range in cultures with medium
change at 24 and 48 hours, but in contrast
the pH consistently fell below 7 1 in
sealed tube cultures. Significantly, no
response occurred in sealed tube cultures
whilst a response to PHA could be
measured in both types of culture with
modified conditions.
In cultures containing normal lympho-
cytes the PHA responses in sealed tube
and medium change cultures were similar
(pH in the culture period in the range
7X1-7X3) whereas in loose capped cultures
the PHA response was markedly reduced
and the pH increased to 7-9-8 1.
DISCUSSION
Sera from the majority of patients
with AML inhibited the in vitro response
to PHA of both autologous lymphocytes
and allogeneic normal lymphocytes. This
occurred only in the appropriate culture
conditions and especially during the
acute phase or in relapse. Similarly,
mixed lymphocyte reactions were inhi-
bited by some of the same AML sera,
further suggesting that in vivo immune
responses could be impaired by factors
present in these sera. These observa-
tions may explain the reduced delayed
hypersensitivity responses in AML which
have been reported by some workers
(Hersh et al., 1971; Dupuy et al., 1971).
Inhibitors of the lymphocyte response
to PHA occur in sera from patients with
a wide variety of clinical conditions
including uraemia (Silk, ] 967a), cancer
(Silk, 1967b), Hodgkin's disease (Trubo-
vitz, Masek and Del Rosario, 1966),
idiopathic steatorrhoea (Winter et al.,
1967), syphilis (Levene et al., 1969),
multiple sclerosis and cirrhosis (Knowles
et al., 1968), ataxia telangiectasia (McFar-
lin and Oppenheim, 1969), advanced
alcoholic cirrhosis (Hsu and Leevy, 1971),
and also in normal foetal plasma (Ayoub
and Kasakura, 1971), normal pregnancy
sera (Walker, Freeman and Harris, 1972)
and normal sera containing HL-A anti-
bodies (Ceppellini, 1971). Normal serum
itself, when present in cultures at high
concentrations, is inhibitory (Cooperband
et al., 1967). Thus, many different inhibi-
tory factors may be involved both
specific, for example HL-A antibodies,
but probably mostly nonspecific. In one
example an a globulin fraction separated
and concentrated from NHS was found
to be immunosuppressive when added to
mitogen stimulated and mixed leucocyte
cultures (Cooperband et al., 1969).
Even in cases of AML with a high
circulating primitive cell count the main-
tenance of physiological pH in cultures
resulted in a significant PHA response by
lymphocytes suspended in allogeneic nor-
mal serum. Similarly, in most cases
where a serum was inhibitory with auto-
logous lymphocytes a normal response
could be measured if the PHA concen-
tration was increased. Our evidence thus
demonstrates that circulating PHA res-
ponsive cells in treated and untreated
AML, even in the presence of high
leukaemia blast counts and during inten-
sive chemotherapy, can be induced to
respond in vitro. Indeed, the lympho-
cytes of 3 patients with AML studied
during consolidation therapy with cyclo-
phosphamide and thioguanine had an
apparently increased PHA response, an
observation which may be explained by
the relative susceptibility to cyclophos-
phamide of " B " lymphocytes and a
consequent increase in the relative num-
bers of " T " cells responsive to PHA.
These studies show that the inhibitory
effect of leukaemia serum and the appa-
rent inhibition due to changes in culture
conditions when large numbers of blastoid
cells are present must be considered when
in vitro lymphocyte reactivity in AML is
measured.
In vivo it may be important to dis-
tinguish between intrinsic cellular defects
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and the effect of circulating inhibitory
factors. The absence in most cases of
inhibitory factors during remission might
indicate normal " T " lymphocyte reac-
tivity in these patients, whilst the prompt
induction of HL-A alloantibodies in a
patient receiving immunotherapy indi-
cates that at least some aspects of " B"
cell function were effective in this patient
during remission.
Disturbance of the proportions of
various lymphocyte classes and the pre-
sence ofinhibitors, whether specific immu-
noglobulins or nonspecific and hetero-
geneous, may be secondary concomitants
of leukaemia and chemotherapy which
interfere with a specific immunological
response. Thus, cellular immunosuppres-
sive activity might prove to be of impor-
tance in the maintenance and progress of
the disease.
Studies are now in progress which will
relate the clinical response of patients
with AML to the results of these immuno-
logical tests and will be reported else-
where.
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